Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-07-19
2011-07-19
Rawlings, Stephen L (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C436S065000, C530S350000, C536S023500, C536S024330
Reexamination Certificate
active
07981610
ABSTRACT:
It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA or protein.
REFERENCES:
patent: 5776696 (1998-07-01), Salowe
patent: 5783398 (1998-07-01), Marcy et al.
patent: 6251620 (2001-06-01), Hatada et al.
patent: WO 98/45704 (1998-10-01), None
patent: WO 00/27428 (2000-05-01), None
patent: WO 01/55307 (2001-08-01), None
patent: WO 01/64886 (2001-09-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/14281 (2002-02-01), None
Klein et al. (J. Exp. Med. 2001; 194: 1625-1638).
Wiestner et al. (Blood. Jun. 15, 2003; 101: 4944-4951).
Crespo et al. (N. Engl. J. Med. May 1, 2003; 348: 1764-1775).
Orchard et al. (Lancet. Jan. 10, 2004; 363: 105-111).
Chen et al. (Blood. Dec. 15, 2002; 100 (13): 4609-4614).
Rosenwald et al. (J. Exp. Med. Dec. 3, 2001; 194 (11): 1639-1647).
Bannerji et al., “Update on the Biology of Chronic Lymphocytic Leukemia,”Curr. Opin. Oncol.12:22-29, 2000.
Caligaris-Cappio et al., “B-cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather,”J. Clin. Oncol.17(1):399-408, Jan. 1999.
Caligaris-Cappio, “Biology of Chronic Lymphocytic Leukemia,”Rev. Clin. Exp. Hematol.4(1):5-21, 2000.
Capello et al., “Identification of Three Subgroups of B Cell Chronic Lymphocytic Leukemia Based Upon Mutations of BCL-6 and IgV Genes,”Leukemia14(5):811-815, May 2000.
Catherwood et al. (Eur. J. Haematol. 2006; 76: 294-298).
Chan et al., “ZAP-70: a 70 kd Protein-Tyrosine Kinase That Associates with the TCR Zeta Chain,”Cell71(4):649-662, Nov. 1992.
Crespo et al. (N. Engl. J. Med. May 1, 2003; 348 (18): 1764-1775).
D'Arena et al., “CD69 Expression in B-Cell Chronic Lymphocytic Leukemia: A New Prognostic Marker?”Haematolgica86:995-996, Sep. 2001.
Damle et al., “Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia,”Blood94:1840-1847, 1999.
Damle et al., “Updated Data on V Gene Mutation Status and CD38 Expression in B-CLL,”Blood95:2456-2457, 2000 (Response to Hamblin, 2000).
De Plaen et al. (Immunogenectics. 1994; 40: 360-369).
Fargnoli et al., “Diminished TCR Signaling in Cutaneous T Cell Lymphoma is Associated With Decreased Activities of Zap70, Syk and Membrane-Associated Csk,”Leukemia11(8)1338-1346, Aug. 1997.
Garcia et al., “Diagnostic Usefulness of CD23 and FMC-7 Antigen Expression Patterns in B-cell Lymphoma Classification,”Am. J. Clin. Pathol.115:258-265, Feb. 2001.
GenBank Accession No. L05148, Aug. 3, 1993.
GenBank Accession No. XM—047776, Feb. 7, 2002.
Hamblin et al., “Immunoglobulin V Genes and CD38 Expression in CLL,”Blood95:2455-2456, 2000.
Hamblin et al., “Unmutated Ig VHGenes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia,”Blood94(6):1848-1854, Sep. 15, 1999.
Kim et al. (Leuk. Lymphoma. Oct. 2004; 45 (10): 2037-2045).
Klein et al., “Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B cells,”J. Exp. Med.194(11):1625-1638, Dec. 3, 2001.
Knauf et al., “Prognostic Impact of the Serum Levels of Soluble CD23 in B-Cell Chronic Lymphocytic Leukemia,”Blood89(11):4241-4242, 1997.
Koyasu et al., “Delineation of a T-cell Activation Motif Required for Binding of Protein Tyrosine Kinases Containing Tandem SH2 Domains,”Proc. Natl. Acad. Sci. USA91:6693-6697, Jul. 1994.
Kuroyama et al. (Biochem. Biophys. Res. Comm. 2004; 315: 935-941).
Kurt et al. (Int. J. Cancer. 1998; 78: 16-20).
Naylor and Capra, “Mutational Status of Ig VHGenes Provides Clinically Valuable Information in B-Cell Chronic Lymphocytic Leukemia,”Blood94(6):1837-1839, Sep. 15, 1999.
Nel et al., “Ligation of the T-cell Antigen Receptor (TCR) Induces Association of hSos1, ZAP-70, Phospolipase C-γ1, and Other Phosphoproteins with Grb2 and the ζ-Chain of the TCR,”J. Biol. Chem.270(31):18428-18436, Aug. 4, 1995.
Northrop et al., “Characterization of the Roles of SH2 Domain-Containing Proteins in T-Lymphocyte Activation by Using Dominant Negative SH2 Domains,”Mol. Cell. Biol.16(5):2255-2263, 1996.
Orchard et al. (Leuk. Lymphoma. Dec. 2005; 46 (12): 1689-1698).
Pasqualucci et al., “BCL-6 Mutations are Associated With Immunoglobulin Variable Heavy Chain Mutations in B-cell Chronic Lymphocytic Leukemia.”Cancer Res.60(20):5644-5648, Oct. 15, 2000.
Paz et al., “Mapping the Zap-70 Phosphorylation Sites on LAT (linker for activation of T cells) Required for Recruitment and Activation of Signaling Proteins in T Cells,”Biochem. J.356:461-471, 2001.
Rassenti and Kipps, “Expression of Ig-β (CD79b) by Chronic Lymphocytic Leukemia B Cells That Lack Immunoglobulin Heavy-Chain Allelic Exclusion,”Blood95(8):2725-2727, Apr. 15, 2000.
Rassenti and Kipps, “Lack of Extensive Mutations in the VH5 Genes Used in Common B Cell Chronic Lymphocytic Leukemia.”J. Exp. Med.177(4):1039-1046, Apr. 1, 1993.
Rassenti et al. (N. Engl. J. Med. Aug. 26, 2004; 351 (9): 893-901).
Rosenwald et al., “Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia,”J. Exp. Med.194(11):1639-1647, Dec. 3, 2001.
Sarfati et al., “Prognostic Importance of Serum Soluble CD23 Level in Chronic Lymphocytic Leukemia,”Blood88(11):4259-4264, Dec. 1, 1996.
Skolnick et al. (Trends in Biotechnology. 2000; 18: 34-39).
Swerdlow, “Small B-Cell Lymphomas of the Lymph Nodes and Spleen: Practical Insights to Diagnosis and Pathogenesis,”Mod. Pathol.12(2):125-140, 1999.
Tworek et al., “Flow Cytometric and Immunohistochemical Analysis of Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, and Plasmacytoid Small Lymphocytic Lymphoma,”Am. J. Clin. Pathol.110(5):582-589, 1998. (Abstract only).
Voss et al., “Correlation of Clinical Data with Proteomics Profiles in 24 Patients with B-Cell Chronic Lymphocytic Leukemia,”Int. J. Cancer91:180-186, 2001.
Wang, “Wang web page,” http://www.bloodctrwise.org/research/faculty/Wang/wang.html, pp. 1-4, accessed Mar. 4, 2002.
Wiestner (Blood. Mar. 1, 2005; 105 (5): 1839-1840).
Wiestner et al., “ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile,”Blood101(12):4944-4951, 2003.
Wiestner et al., “Zap70 Expression is a Distinctive Feature of B-CLL With Unmutated Immunoglobulin Genes and Can Be Useful for Diagnostic Application,” 70éme Assemblée annuelle de la SSMI / 70. Jahresversammlung der SGIM (Société Suisse de la Médecine Interne (SSMI)), Abstract, available on Internet as early as Apr. 25, 2002.
Xu et al., “Assessment of CD10 in the Diagnosis of Small B-Cell Lymphomas: A Multiparameter Flow Cytometric Study,”Am. J. Clin. Pathol.117(2):291-300, Feb. 2002.
Zhang and Siraganian, “CD45 is Essential for FcεRI Signaling by ZAP70, but not Syk, in Syk-Negative Mast Cells,”J. Immunol.163:2508-2516, 1999.
Branch, “A good antisense molecule is hard to find”,Trends Biochem. Sci., vol. 23, pp. 45-50, 1998.
Gauen et al., “Interactions of p59fynand ZAP-70 with T-Cell Receptor Activation Motifs: Defining the Nature of a Signaling Motif”,Molecular and Cellular Biology, vol. 14, No. 6, pp. 3729-3741, 1994.
Longo et al., “The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease”,Leukemia, vol. 21, pp. 110-120, 2007.
To
Barry Todd S.
Rosenwald Andreas
Staudt Louis M.
Wiestner Adrian
Wilson Wyndham
Klarquist & Sparkman, LLP
Rawlings Stephen L
The United States of America as represented by the Department of
LandOfFree
ZAP-70 expression as a marker for chronic lymphocytic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ZAP-70 expression as a marker for chronic lymphocytic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ZAP-70 expression as a marker for chronic lymphocytic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2711687